Virtual Bioequivalence: a myth or coming reality? [Dissolution / BCS / IVIVC]

posted by mittyri – Russia, 2018-06-10 00:39 (2137 d 10:46 ago) – Posting: # 18878
Views: 7,530

Dear All!

I was looking into the abstracts published after annual PAGE meeting (and had a pleasure to discuss it with some authors).
I collected some of them here for your review:
  1. In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone
  2. Automatic framework for bioequivalence studies from In Vitro test to In Vivo study design
  3. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles
  4. Selecting in vitro dissolution tests using population pharmacokinetic modelling to help bioequivalence studies
  5. Bayesian knowledge integration for an in vitro–in vivo correlation (IVIVC) model
The investigators are actively trying to raise the level of the models from in vivo level to in vitro in vivo level.
AFAIK regulatories are also interested and funding some of them.
What do you think? Is time of deconvolution over? Could we see new class A IVIVC using that approach soon?
—
Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,650 registered users;
44 visitors (0 registered, 44 guests [including 6 identified bots]).
Forum time: 11:25 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5